Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health (GH) is a leader in precision oncology, pioneering non-invasive liquid biopsy tests for cancer detection and monitoring. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's financial performance, clinical advancements, and strategic initiatives.
Access authoritative coverage of earnings reports, regulatory milestones, and technology innovations shaping cancer diagnostics. Our curated collection includes press releases on clinical trial results, partnership announcements, and peer-reviewed research developments directly from Guardant Health's communications.
Key updates cover FDA clearances for diagnostic assays, global commercialization efforts, and data partnerships advancing precision medicine. Stay informed about developments in molecular residual disease detection, expanded test indications, and reimbursement progress affecting healthcare adoption.
Bookmark this page for consolidated access to verified information about liquid biopsy advancements and GH's role in transforming cancer care through genomic insights. Check regularly for objective reporting on developments impacting both clinical practice and investment considerations.
Guardant Health (Nasdaq: GH) announced positive results from the RADIOHEAD study, conducted in collaboration with the Parker Institute for Cancer Immunotherapy (PICI). The study evaluated Guardant Reveal, a tissue-free monitoring tool for detecting immunotherapy responses in advanced cancer patients.
The research, published in Cancer Research Communications, analyzed over 500 patients with various advanced solid tumors. Key findings showed that Guardant Reveal could identify non-responders up to 5 months earlier than standard methods. Patients with ≥80% decrease in tumor fraction showed a 75% lower risk of progression. The study covered multiple cancer types, including lung, skin, head and neck, breast, GI, GU, and gynecologic cancers.
Guardant Health (Nasdaq: GH) announced the enrollment of the first patient in the National Cancer Institute's Vanguard Study, which will evaluate the company's Shield Multi-Cancer Detection (MCD) test. The four-year study aims to enroll up to 24,000 participants aged 45-75 who are cancer-free.
The Shield MCD test, which recently received FDA Breakthrough Device Designation, can screen for 10 different cancer types through a simple blood draw. The test was selected based on its performance in detecting lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver, and gastric cancers. The study's results will inform the design of a larger randomized controlled trial for cancer screening evaluation.
Guardant Health (NASDAQ: GH), a precision oncology company, has scheduled its Q2 2025 earnings release for July 30, 2025, after market close. Management will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day.
The earnings webcast will be accessible through the Investors section of Guardant Health's website, with a replay available after the event.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
